Prosecution Insights
Last updated: October 02, 2026

Examiner: DANIEL, ANTARIUS S

Tech Center 3700 • Art Units: 3783 3791

This examiner grants 52% of resolved cases

Analysis

Antarius S. Daniel is an examiner in Tech Center 3700, assigned to Art Unit 3783. He has 192 resolved cases with an allowance rate of 52.1%. This figure suggests that about half of the applications he reviews are granted. The interview lift is 15.7%, indicating that interviews provide a meaningful boost to the probability of success.

The median days to allowance for this examiner is 1269. This timeline indicates a prosecution cycle of approximately three and a half years. For practitioners, the 192 resolved cases offer a clear view of his tendencies. The 52.1% allowance rate and the 15.7% interview lift suggest that applicants should be prepared for a challenging and potentially long process. In Art Unit 3783, the 1269-day median pendency is an important benchmark for managing expectations and developing a prosecution strategy.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

52.1%
Allow Rate
-17.9% vs TC avg
240
Total Applications
+15.7%
Interview Lift
1269
Avg Prosecution Days
Based on 192 resolved cases, 2023–2026

Rejection Statute Breakdown

0.9%
§101 Eligibility
17.2%
§102 Novelty
53.7%
§103 Obviousness
25.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17868546 INJECTABLE MATERIALS DELIVERY DEVICES, SYSTEMS, AND METHODS Non-Final OA BOSTON SCIENTIFIC SCIMED, INC.
17854923 WOUND CLOSURE SYSTEMS, DEVICES AND METHODS INCORPORATING THERAPEUTIC DEVICES Final Rejection Cilag GmbH International
18733281 ELONGATE INSTRUMENT AND ELONGATE INSTRUMENT GUARD MEMBER COMPATIBILITY Non-Final OA INTUITIVE SURGICAL OPERATIONS, INC.
17597990 ACTIVE MICRONEEDLES FOR ENHANCED PAYLOAD UPTAKE Non-Final OA The Regents of the University of California
17636913 TUBE SECUREMENT SYSTEM Non-Final OA SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
17273407 PEDIATRIC CATHETER Non-Final OA Vanderbilt University
18530925 SWITCH CHANNEL STAY-ON HEMOSHIELD CONNECTOR Final Rejection CareFusion 303, Inc.
18111138 PROTECTIVE COVER Non-Final OA The Cleveland Clinic Foundation
18051221 GUIDE CATHETER EXTENSION SYSTEM FOR REVERSE CONTROLLED ANTEGRADE/RETROGRADE TRACKING & THROMBUS REMOVAL PROCEDURES Non-Final OA VANTIS VASCULAR, INC.
16132878 INTRAVASCULAR DELIVERY SYSTEM AND METHOD FOR PERCUTANEOUS CORONARY INTERVENTION Non-Final OA VANTIS VASCULAR, INC.
18115189 Catheter Component Securement Apparatus and Associated System Final Rejection Becton, Dickinson and Company
18093208 Catheter Adapter with Integrated Adhesive Dispenser Non-Final OA Becton, Dickinson and Company
18092592 Management of Catheters and Accessories During Intravascular Catheter Maintenance Non-Final OA Becton, Dickinson and Company
17045834 Universal Cap For Male And Female Connectors Non-Final OA Becton, Dickinson and Company
18706198 DRUG DELIVERY DEVICE, DRUG RESERVOIR UNIT AND SET Non-Final OA Sanofi
18649253 DEVICE FOR PREPARING AND DISPENSING ACTIVE INGREDIENT SOLUTIONS Non-Final OA Heraeus Medical GmbH
17478788 INFUSION PUMP WITH PATIENT WEIGHT CHECK Non-Final OA ICU Medical, Inc.
18796975 HEMOSTASIS VALVE Non-Final OA Merit Medical Systems, Inc.
17637520 ACTIVATABLE INJECTION DEVICE FOR DRUG DELIVERY Non-Final OA AMGEN INC.
17439970 MEDICAL DEVICE WITH DRUG-ELUTING COATING ON MODIFIED DEVICE SURFACE Non-Final OA Bard Peripheral Vascular, Inc.
18035939 SKIN PATCH DRUG INFUSION SYSTEM Final Rejection MEDTRUM TECHNOLOGIES INC.
18762678 NEEDLE ASSEMBLY AND DRUG INJECTION DEVICE COMPRISING SAME Non-Final OA EOFLOW CO., LTD.
18488900 SYSTEMS AND METHODS FOR ASPIRATION AND MONITORING Non-Final OA INCUVATE, LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month